ＷＨＯ、日本のワクチン承認　エムポックスで２例目

　【パリ時事】世界保健機関（ＷＨＯ）は１９日、アフリカ中部コンゴ（旧ザイール）などで広がっている天然痘に似た症状の感染症「エムポックス（サル痘）」の予防薬として、日本のＫＭバイオロジクス（熊本市）製ワクチンの緊急使用を認めた。ＷＨＯによるエムポックスワクチンの承認は２例目。
　ＫＭバイオ製ワクチンは、日本国内では２０２２年に承認済み。ＷＨＯが緊急使用を認めたことで、途上国などで普及促進が期待される。
　中谷祐貴子ＷＨＯ事務局長補は「重要な一歩。子どもを含むすべての人々を守る新たな選択肢の提供だ」と述べた。（2024/11/20-08:56）

The World Health Organization on Tuesday approved the emergency use of a mpox vaccine made by Japan's KM Biologics Co.
   The LC16m8 vaccine, which was approved in Japan in 2022, became the second mpox vaccine to be approved by the WHO.
   The move "marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children," Yukiko Nakatani, WHO assistant director-general for access to medicines and health products, said in a statement.
   The Japanese government has announced that it will donate 3.05 million doses of the LC16m8 vaccine, along with specialized inoculation needles, to the Democratic Republic of the Congo. "This is the largest donation package announced to date in response to the current mpox emergency," the WHO said.